Zinc may help stave off respiratory infection symptoms, study finds
A zinc supplement might help stave off the symptoms of respiratory tract infections, such as coughing, congestion, and sore throat, and cut illness duration, suggests a pooled analysis of the available evidence published in the journal BMJ Open. But the quality of the evidence on which these findings are based is variable, and it’s not clear what an optimal formulation or dose of this nutrient might be, the researchers said.
Respiratory tract infections include colds, flu, sinusitis, pneumonia, and the novel coronavirus (COVID-19). Most infections clear up by themselves, but not all. Additionally, they often prove costly in terms of their impact on health services and time taken in sick leave.
Zinc has a key role in immunity, inflammation, tissue injury, blood pressure and in tissue responses to lack of oxygen. As a result, it has generated considerable interest during the current pandemic for the possible prevention and treatment of COVID-19 infection.
In response to calls for rapid evidence appraisals to inform self-care and clinical practice, the researchers evaluated zinc for the prevention and treatment of SARS-CoV-2, the virus that causes COVID-19, and other viral respiratory tract infections.
When that review was published, the results of several relevant clinical trials weren’t yet available, so this current review brings the available evidence up to date. The review includes 28 clinical trials involving 5446 adults, published in 17 English and Chinese research databases up to August 2020. None of the trials specifically looked at the use of zinc for the prevention or treatment of COVID-19.
The most common zinc formulations used were lozenges followed by nasal sprays and gels containing either zinc acetate or gluconate salts. Doses varied substantially, depending on the formulation and whether zinc was used for prevention or treatment.
Pooled analysis of the results of 25 trials showed that compared with dummy treatment (placebo), zinc lozenges or nasal spray prevented 5 respiratory tract infections in 100 people a month. These effects were strongest for curbing the risk of developing more severe symptoms, such as fever and influenza-like illnesses. This is based on only three studies.
On average, symptoms cleared up two days earlier with the use of either a zinc spray or liquid formulation taken under the tongue than when a placebo was used. During the first week of illness, participants who used sublingual or nasal spray zinc were nearly twice as likely to recover as those who used placebo: 19 more adults out of 100 were likely to still have symptoms a week later if they didn’t use zinc supplements.
While zinc wasn’t associated with an easing in average daily symptom severity, it was associated with a clinically significant reduction in symptom severity on day three.
Side effects, including nausea and mouth and nose irritation, were around 40 percent more likely among those using zinc, but no serious side effects were reported in the 25 trials that monitored them. However, compared with placebo, sublingual zinc didn’t reduce the risk of developing an infection or cold symptoms after inoculation with human rhinovirus, nor were there any differences in illness duration between those who used zinc supplements and those who didn’t. Nor was the comparative effectiveness of different zinc formulations and doses clear. The quality, size, and design of the included studies also varied considerably, the researchers said.
How exactly zinc might exert its therapeutic effects on respiratory infections, including COVID-19, warrants further research, the researchers said.